Testosterone therapy for women: FDA approval, off-label prescribing, and compounded products

No testosterone product is FDA approved in the United States specifically for female sexual dysfunction. That does not make every prescription unlawful: a licensed clinician may prescribe an approved testosterone drug off label, and a pharmacy may compound a patient-specific product under applicable law. But neither path becomes “FDA-approved testosterone for women,” and each needs an exact product, rationale, exposure, evidence, and monitoring record.¹²⁴

The phrase “female testosterone” can refer to a manufactured male-labeled gel used in a different amount, a compounded cream, a pellet, an injection, or another formulation. Those are not interchangeable delivery options.

Separate four regulatory questions

An approved testosterone product prescribed to a woman remains an FDA-approved drug used off label; the drug does not lose its approval, but FDA has not approved that product for the new patient population or claim. A compounded preparation is not an FDA-approved finished product and does not undergo the same premarket review.¹⁴

A consultation should define the proposed job

“Hormone optimization,” “balance,” “vitality,” “anti-aging,” and “low T” do not identify a validated condition or endpoint. Ask the clinician to document the symptom or concern being evaluated, other possible contributors, the evidence-based indication being considered, and how improvement would be measured.

The professional guideline cited here addresses systemic testosterone for a defined sexual-health diagnosis in women; it does not validate testosterone for every fatigue, body-composition, mood, cognition, or longevity claim.³ Evidence tied to one population and endpoint should not be repackaged as a general wellness benefit.

This page does not diagnose a condition or recommend treatment. It provides a record framework for evaluating a proposal with the prescribing clinician.

Formulation changes exposure and reversibility

Routes differ in how easily exposure can be adjusted or stopped, how concentrations fluctuate, what transfer or administration risks exist, and how quickly an adverse effect can be addressed.

• Manufactured gel or solution used off label: preserves FDA-reviewed manufacturing and product labeling, but the female use and amount are not FDA-approved.
• Compounded topical product: can be made in a prescribed concentration, but the finished product is not FDA approved and the pharmacy record matters.
• Injection: creates a formulation- and interval-specific exposure; vague “monthly hormone shot” language is inadequate.
• Pellet: requires a procedure and cannot be removed or adjusted as simply as stopping a daily topical product. The pellet-versus-other-routes guide covers that separate route decision.

Ask how the proposed form supports the intended exposure, how changes are made, and what happens if the effect is excessive or unwanted.

“Bioidentical” does not resolve approval or quality

Testosterone can be chemically identical to endogenous hormone in both approved and compounded products. “Bioidentical” therefore does not tell you whether the finished product was FDA approved, whether the use is on label, which pharmacy made it, or whether a pellet or cream has evidence for the proposed claim.

The compounded-hormone guide explains why active ingredient, finished product, route, and marketing claim must be audited separately.

For a compounded product, preserve:

• pharmacy legal name, address, and license;
• prescription and prescriber;
• active ingredient, base, and other ingredients;
• concentration and delivered amount;
• lot or batch and beyond-use date;
• storage and administration instructions;
• adverse-event and recall contact;
• reason the compounded preparation is used instead of an available approved option.

Monitoring should follow the claim and exposure

A complete plan begins before the first dose. It records relevant history, current medicines and supplements, baseline examination or testing chosen by the clinician, the intended exposure range, and the timing of symptom and laboratory reassessment. The professional guideline describes counseling and monitoring considerations for the population it addresses.³

Ask the prescriber which findings would lead to a lower exposure, a different route, stopping treatment, or evaluation for another cause. Monitoring is not proof that the underlying marketing claim is valid; it is one part of responsible prescribing.

Avoid packages that treat a proprietary “optimal” laboratory range as a diagnosis or guarantee. A result is interpreted within the laboratory method, timing, symptoms, medication exposure, and clinical context.

Read benefit and harm claims at the same level of precision

Separate evidence about one symptom domain from claims about muscle, fat, energy, mood, memory, cardiovascular outcomes, or healthy aging. Ask whether the study population resembles the proposed patient, which formulation and exposure were tested, how long follow-up lasted, what comparator was used, and which outcomes were actually measured.

The FDA’s testosterone materials also make clear that labeling and safety information evolve with reviewed evidence.¹² Current labeling for the exact manufactured product—not a clinic’s generic consent form—is the regulatory reference.

Make the testosterone proposal product-specific

• Defined clinical question and accountable prescriber
• Exact manufactured or compounded finished product
• On-label or off-label status stated plainly
• Route, concentration, delivered amount, and schedule
• Pharmacy and lot/batch record when compounded
• Evidence tied to the proposed population and endpoint
• Baseline and follow-up plan
• Adjustment, stopping, adverse-effect, and urgent-contact rules

Take the exact product question back to the prescriber

Ask: “What exact finished testosterone product are you prescribing, is this population and indication in its FDA-approved label, what evidence supports my specific treatment goal, and how will exposure be measured, adjusted, and stopped?” A clear answer should not depend on the word “bioidentical.”